经营业绩： 重大事项： 创胜集团-B(06628)合作伙伴Inhibrx公布ozekibart治疗软骨肉瘤的 II期临床试验积极结果，计划于2026年 递交BLA的业绩进展 君圣泰医药-B(02511)：全球首创抗炎代谢调节剂HTD1801完成2型糖尿病III期临床研究 展现持续52周的 综合获益与安全性优势 中国铁建(01186)拟斥资110亿元收购中铁十一局约18.38%股权、中铁建设14.36%股权、铁建投资12.66% 股权及昆仑投资29.23%股权 瑞风新能源(00527)拟在老挝部署约34万台改良型清洁炉灶 预计十年周期内总减排量约270万吨二氧化碳 当量 谭木匠(00837)品牌提升战略落地北京 从单一产品销售向文化传播与品牌价值综合输出转型 中国同辐(01763)突破呼气诊断关键原料技术 成为完整掌握呼气试验产品全产业链的龙头企业 帝国科技集团(00776)与光合星云订立谅解备忘录 拟合作开发AI漫剧呈现电竞IP精神 友邦保险(01299)第三季度新业务价值同比上升25%至14.76亿美元 11个市场实现双位数字增长 鹰普精密(01286)第三季度实现收入约13.61亿港元，同比增长16.8% ...

两项研究中，HTD1801对多项心肾代谢指标的改善在52周时均持续获益，显示其在长期治疗中具有血 糖控制之外的综合获益优势 两项研究中，双盲期HbA1c达标(HbA1c <7.0%)的患者比例在第52周时仍保持稳定。与此同时， HTD1801在降低血脂方面的疗效亦长期稳定，包括低密度脂蛋白胆固醇(LDL-C)与非高密度脂蛋白胆固 醇(non-HDL-C)均显著下降。HTD1801长期治疗还可持续降低与心血管事件及T2DM患者临床结局密切 相关的炎症标记物γ－谷氨酰转移酶(GGT)和超敏C反应蛋白(hs-CRP)。 值得关注的是，全体患者的估算肾小球滤过率(eGFR)在治疗期间保持稳定。在合并轻度肾功能损害的 患者中，第24周观察到的eGFR改善在第52周时仍然保持，显示HTD1801的肾脏保护潜力。相关数据将 在近期学术会议公布。 良好的安全性与耐受性 格隆汇10月31日丨君圣泰医药-B(02511.HK)宣布，HTD1801在2型糖尿病(T2DM)患者中开展的两项III期 临床试验(SYMPHONY-1和SYMPHONY-2)已顺利完成，52周研究(含开放标签延长期(OLE))取得积极的 疗效与安全性结果。 ...

两项III期临床研究的52周数据充分验证了HTD1801疗效的持久性，并进一步凸显其为T2DM患者带来的 长期综合临床获益。君圣泰医药计划于今年内向国家药品监督管理局(NMPA)药品审评中心(CDE)递交 HTD1801治疗T2DM适应症的新药上市申请(NDA)。 两项研究中，双盲期HbA1c达标(HbA1c<7.0%)的患者比例在第52周时仍保持稳定。与此同时， HTD1801在降低血脂方面的疗效亦长期稳定，包括低密度脂蛋白胆固醇(LDL-C)与非高密度脂蛋白胆固 醇(non-HDL-C)均显着下降。HTD1801长期治疗还可持续降低与心血管事件及T2DM患者临床结局密切 相关的炎症标记物γ-谷氨酰转移酶(GGT)和超敏C反应蛋白(hs-CRP)。 HTD1801在长期治疗中展现出良好的安全性与耐受性，与双盲期结果保持一致。对于接受HTD1801治 疗的患者，治疗期延长不会增加其不良事件的类型与严重程度。 君圣泰医药-B(02511)公布，HTD1801在2型糖尿病(T2DM)患者中开展的两项III期临床试验 (SYMPHONY-1和SYMPHONY-2)已顺利完成，52周研究(含开放标签延长期(OLE)) ...

智通财经APP讯，君圣泰医药-B(02511)公布，HTD1801在2型糖尿病(T2DM)患者中开展的两项 III期临 床试验(SYMPHONY-1和SYMPHONY-2)已顺利完成，52周研究(含开放标签延长期(OLE))取得积极的疗 效与安全性结果。 两项III期临床研究的52周数据充分验证了HTD1801疗效的持久性，并进一步凸显其为T2DM患者带来的 长期综合临床获益。君圣泰医药计划于今年内向国家药品监督管理局(NMPA)药品审评中心(CDE)递交 HTD1801治疗T2DM适应症的新药上市申请(NDA)。 两项研究中，双盲期HbA1c达标(HbA1c <7.0%)的患者比例在第52周时仍保持稳定。与此同时， HTD1801在降低血脂方面的疗效亦长期稳定，包括低密度脂蛋白胆固醇(LDL-C)与非高密度脂蛋白胆固 醇(non-HDL-C)均显着下降。HTD1801长期治疗还可持续降低与心血管事件及T2DM患者临床结局密切 相关的炎症标记物 γ-谷氨酰转移酶(GGT)和超敏C反应蛋白(hs-CRP)。 HTD1801在长期治疗中展现出良好的安全性与耐受性，与双盲期结果保持一致。对于接受HTD1801治 疗 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 HighTide Therapeutics, Inc. （於開曼群島註冊成立的有限公司） （股份代號：2511） 全球首創抗炎代謝調節劑HTD1801完成2型糖尿病III期臨床研究 展現持續52周的綜合獲益與安全性優勢 本公告由君聖泰醫藥（「本公司」，連同其附屬公司統稱為「本集團」）自願發佈，以 告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事會（「董事會」）宣佈，HTD1801在2型糖尿病(T2DM)患者中開展的兩項 III期臨床試驗（SYMPHONY-1和SYMPHONY-2）已順利完成，52周研究（含開放 標籤延長期(OLE)）取得積極的療效與安全性結果。 52周研究結果進一步驗證，HTD1801可調節代謝、抑制炎症並改善腎功能，有潛 力作為差異化療法從多維度改善2型糖尿病的疾病進程 兩項III期臨床研究的52周數據充分驗證了HTD1801療效的持久性，並進一步凸顯 其為T2DM患 ...

Core Viewpoint - The innovative drug sector, particularly the company Junshengtai Pharmaceutical, has shown remarkable performance in the Hong Kong stock market, with its stock price increasing by over 233.07% year-to-date as of September 22, 2025, driven by strong recognition of its innovation capabilities in the treatment of Cardiovascular-Kidney-Metabolic Syndrome (CKM) [1][4]. Market Overview - Junshengtai Pharmaceutical is entering a long-underestimated market worth hundreds of billions, specifically targeting CKM, which encompasses complex diseases involving multiple organ interactions, including heart disease, chronic kidney disease (CKD), and various metabolic disorders [5]. - The global metabolic disease market is projected to reach $458 billion by 2032, with CKM affecting nearly 90% of American adults and 80% of Chinese adults, highlighting a significant unmet clinical need [5]. Product Innovation - The core product HTD1801 utilizes a unique dual mechanism of "AMPK activation + NLRP3 inhibition," demonstrating systemic therapeutic advantages by addressing insulin resistance and reducing inflammation [6]. - HTD1801 is being developed globally for various CKM-related diseases, including type 2 diabetes (T2DM), metabolic-associated fatty liver disease (MASH), CKD, obesity, and others [7]. Clinical Data and Efficacy - Recent clinical data from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have shown that HTD1801 significantly reduces HbA1c levels and improves lipid profiles and inflammation markers in T2DM patients [9][10]. - HTD1801 also shows potential in improving kidney function in CKD patients without causing electrolyte imbalances, indicating its safety and therapeutic potential [10]. Strategic Development - The company is enhancing its R&D investments, with a reported expenditure of 106.4 million yuan, and is advancing multiple clinical trials for HTD1801, which is positioned as a multi-indication drug [13]. - 2025 is set to be a pivotal year for the company, with plans to initiate new drug application (NDA) for T2DM and advance II-phase studies for CKD, indicating a strong commercial potential [14]. Valuation Perspective - The current stock price reflects some potential of HTD1801 in the T2DM market, but the broader value in the CKM space remains underappreciated, suggesting a potential revaluation as clinical data continues to emerge [16]. Cultural and Policy Alignment - HTD1801 is developed based on traditional natural products, aligning with modern clinical standards and cultural recognition, positioning the company favorably in a competitive landscape focused on systemic diseases [18].

Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) experienced a nearly 8% increase in stock price, reaching HKD 3.4, with a trading volume of HKD 5.8183 million, following the release of its interim results for the six months ending June 30, 2025 [1] Financial Performance - Other income for the company was RMB 10.542 million, representing a year-on-year decrease of 69.96% [1] - The loss attributable to shareholders was RMB 120 million, which narrowed by 42.96% year-on-year [1] - Basic loss per share was RMB 0.27 [1] Product Development - The company's core product, HTD1801, is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system [1] - HTD1801 is currently under global development for the treatment of CKM-related diseases, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1]

Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) experienced a nearly 8% increase in stock price, reaching HKD 3.4, with a trading volume of HKD 5.8183 million [1] Financial Performance - The company reported a decrease in other income to RMB 10.542 million, a year-on-year decline of 69.96% [1] - Shareholder loss narrowed to RMB 120 million, a year-on-year reduction of 42.96% [1] - Basic loss per share was RMB 0.27 [1] Product Development - The core product HTD1801 is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system [1] - HTD1801 is under global development for treating CKM-related diseases, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), Obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1]

Core Viewpoint - Junsheng Tai Pharmaceutical-B reported a significant reduction in losses for the first half of 2025, with a loss of 113.9 million yuan compared to a loss of 210.9 million yuan in the same period of 2024 [1] Group 1: Financial Performance - The company recorded a loss of 113.9 million yuan in the first half of 2025, which is a substantial improvement from the 210.9 million yuan loss in the first half of 2024 [1] Group 2: Product Development - The core product HTD1801 is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system, currently under development for CKM-related diseases [1] - HTD1801 is being developed for multiple conditions, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), Obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1] - A new indication for HTD1801 has been added for Chronic Kidney Disease, showing potential in regulating various pathogenic mechanisms related to kidney diseases [1] - HTD1801 demonstrates significant therapeutic potential in the CKD field, with advantages in improving eGFR (estimated Glomerular Filtration Rate) trends compared to competing drugs [1] - The company is preparing for a Phase II clinical study of HTD1801 for the treatment of CKD [1] Group 3: Pipeline Candidates - In addition to HTD1801, the company has developed a strong pipeline of innovative candidate drugs, including HTD4010, HTF1037, HTF1057, HTD1804, HTD1805, and HTD2802, targeting ten potential indications [1]

格隆汇8月25日丨君圣泰医药-B(02511.HK)公布中期业绩，2025年上半年，集团录得亏损人民币1.139亿 元，较2024年同期亏损人民币2.109亿元大幅收窄。集团的创新产品管线能够使集团在全球快速增长的 重大代谢疾病治疗市场中抓住机遇。应对代谢疾病及炎症相关共病的核心策略是挖掘HTD1801的潜 力，拓展其适应症范围，目前，HTD1801正在全球范围内开发，用于治疗CKM相关疾病，包括二型糖 尿病(T2DM)、代谢相关脂肪性肝炎(MASH)、慢性肾病(CKD)、肥胖症、原发性硬化性胆管炎(PSC)及 严重高甘油三酯血症(SHTG)。除HTD1801外，集团亦研发出具备同样创新性的强大候选药物管线，包 括HTD4010、HTF1037、HTF1057、HTD1804、HTD1805及HTD2802，集团的产品管线共针对十种潜在 适应症。 HTD1801是唯一通过激活AMPK和抑制NLRP3炎症小体双机制，以解决心肾代谢系统疾病(CKM)的临床 阶段化合物。CKM是一类由心脏疾病、肾脏疾病及代谢紊乱(如糖尿病、肥胖症等)共同构成的复杂健康 障碍。尽管现有标准疗法已取得显着进展，但在CKM相关疾病中仍存 ...